{"id":5338,"date":"2022-03-14T08:42:49","date_gmt":"2022-03-14T07:42:49","guid":{"rendered":"https:\/\/ww2.omceoge.it\/?page_id=5338"},"modified":"2022-03-14T08:42:49","modified_gmt":"2022-03-14T07:42:49","slug":"5338-fnomceo-comunicazione-n-64-aifa-infliximab-remicade-flixabi-inflectra-remsima-e-zessly-uso-di-vaccini-vivi-in-bambini-esposti-al-medicinale-in-utero-o-durante-l-allattamento","status":"publish","type":"post","link":"https:\/\/www.omceoge.it\/home9\/item\/5338-fnomceo-comunicazione-n-64-aifa-infliximab-remicade-flixabi-inflectra-remsima-e-zessly-uso-di-vaccini-vivi-in-bambini-esposti-al-medicinale-in-utero-o-durante-l-allattamento\/","title":{"rendered":"<img src=\"https:\/\/ww2.omceoge.it\/home9\/wp-content\/uploads\/fnomceo.png\" class=\"custom-title-icon\" style=\" vertical-align:middle; display:inline-block;\">FNOMCEO COMUNICAZIONE N 64 &#8211; AIFA &#8211; INFLIXIMAB (REMICADE, FLIXABI, INFLECTRA, REMSIMA E ZESSLY): USO DI VACCINI VIVI IN BAMBINI ESPOSTI AL MEDICINALE IN UTERO O DURANTE L&#8217;ALLATTAMENTO"},"content":{"rendered":"<p>Pubblichiamo la Comunicazione n.64 della FNOMCeO<\/p>\n<hr class=\"readMore\">\n<div class=\"allegati_pdf\">\n<div class=\"div_pdf_js\"><a data-post-title=\"&lt;img src=&quot;https:\/\/ww2.omceoge.it\/home9\/wp-content\/uploads\/fnomceo.png&quot; class=&quot;custom-title-icon&quot; style=&quot; vertical-align:middle; display:inline-block;&quot;&gt;FNOMCEO COMUNICAZIONE N 64 &#8211; AIFA &#8211; INFLIXIMAB (REMICADE, FLIXABI, INFLECTRA, REMSIMA E ZESSLY): USO DI VACCINI VIVI IN BAMBINI ESPOSTI AL MEDICINALE IN UTERO O DURANTE L&#8217;ALLATTAMENTO\" data-context=\"list\" class=\"a_pdf_file\" href=\"\/home8\/media\/k2\/attachments\/Copia_DocPrincipale_Com_n_64.pdf\"><span class=\"span_pdf_icon\">PDF<img data-post-title=\"&lt;img src=&quot;https:\/\/ww2.omceoge.it\/home9\/wp-content\/uploads\/fnomceo.png&quot; class=&quot;custom-title-icon&quot; style=&quot; vertical-align:middle; display:inline-block;&quot;&gt;FNOMCEO COMUNICAZIONE N 64 &#8211; AIFA &#8211; INFLIXIMAB (REMICADE, FLIXABI, INFLECTRA, REMSIMA E ZESSLY): USO DI VACCINI VIVI IN BAMBINI ESPOSTI AL MEDICINALE IN UTERO O DURANTE L&#8217;ALLATTAMENTO\" data-context=\"list\" decoding=\"async\" class=\"img_pdf_js\" src=\"\/home9\/wp-content\/uploads\/pdf-png.png\"><\/span><span class=\"span_pdf_title\">Comunicazione FNOMCeO<\/span><\/a><button type=\"button\" class=\"btn-pdf-preview-trigger\" data-pdf-url=\"\">????<\/button><span class=\"span_pdf_url\"><\/span><\/div>\n<div class=\"div_pdf_js\"><a data-post-title=\"&lt;img src=&quot;https:\/\/ww2.omceoge.it\/home9\/wp-content\/uploads\/fnomceo.png&quot; class=&quot;custom-title-icon&quot; style=&quot; vertical-align:middle; display:inline-block;&quot;&gt;FNOMCEO COMUNICAZIONE N 64 &#8211; AIFA &#8211; INFLIXIMAB (REMICADE, FLIXABI, INFLECTRA, REMSIMA E ZESSLY): USO DI VACCINI VIVI IN BAMBINI ESPOSTI AL MEDICINALE IN UTERO O DURANTE L&#8217;ALLATTAMENTO\" data-context=\"list\" class=\"a_pdf_file\" href=\"\/home8\/media\/k2\/attachments\/Allegato_4.pdf\"><span class=\"span_pdf_icon\">PDF<img data-post-title=\"&lt;img src=&quot;https:\/\/ww2.omceoge.it\/home9\/wp-content\/uploads\/fnomceo.png&quot; class=&quot;custom-title-icon&quot; style=&quot; vertical-align:middle; display:inline-block;&quot;&gt;FNOMCEO COMUNICAZIONE N 64 &#8211; AIFA &#8211; INFLIXIMAB (REMICADE, FLIXABI, INFLECTRA, REMSIMA E ZESSLY): USO DI VACCINI VIVI IN BAMBINI ESPOSTI AL MEDICINALE IN UTERO O DURANTE L&#8217;ALLATTAMENTO\" data-context=\"list\" decoding=\"async\" class=\"img_pdf_js\" src=\"\/home9\/wp-content\/uploads\/pdf-png.png\"><\/span><span class=\"span_pdf_title\">Allegato<\/span><\/a><button type=\"button\" class=\"btn-pdf-preview-trigger\" data-pdf-url=\"\">????<\/button><span class=\"span_pdf_url\"><\/span><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pubblichiamo la Comunicazione n.64 della FNOMCeO<\/p>\n","protected":false},"author":563,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,144],"tags":[],"class_list":["post-5338","post","type-post","status-publish","format-standard","hentry","category-news-dell-ordine","category-news1"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/posts\/5338","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/users\/563"}],"replies":[{"embeddable":true,"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/comments?post=5338"}],"version-history":[{"count":0,"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/posts\/5338\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/media?parent=5338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/categories?post=5338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.omceoge.it\/home9\/wp-json\/wp\/v2\/tags?post=5338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}